Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2017-03-30 Regulatory Filings
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is titled "Selskabsmeddelelse" (Company Announcement) and is dated March 30, 2017. It details a specific operational update regarding a clinical trial (Fase II studiet (CARINA, LYM2001) i NHL videreføres ikke) for a drug (daratumumab) developed by Genmab A/S. This type of announcement, which communicates material, non-public information about clinical trial progress, partnerships, or operational decisions to the market, is characteristic of a general regulatory disclosure. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER), a Dividend Notice (DIV), or a detailed Investor Presentation (IP), and it is a formal company announcement, it best fits the category for general regulatory filings or announcements that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a formal, non-standardized company announcement of this nature, especially since it is a 'Selskabsmeddelelse' (Company Announcement) which often falls under general disclosure rules.
2017-03-30 Danish
Fase II studie med daratumumab til behandling af non-Hodgkin lymfom videreføres ikke til del 2
Regulatory Filings Classification · 95% confidence The document is a formal company announcement ('Selskabsmeddelelse') from Genmab A/S regarding the discontinuation of a specific Phase II clinical trial (CARINA, LYM2001). It provides details on the trial results, the rationale for stopping, and the impact on other ongoing studies. As it is a regulatory announcement regarding company operations and clinical trial status that does not fit into specific categories like financial reports or shareholder voting, it is classified as a general regulatory filing.
2017-03-30 English
Fase II studie med daratumumab til behandling af non-Hodgkin lymfom videreføres ikke til del 2
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding the discontinuation of a specific clinical trial (Phase II study of Daratumumab). It provides details on the trial results, the decision-making process, and the impact on the company's pipeline. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication notice. As it is a regulatory-style announcement regarding clinical trial outcomes, it falls under the 'Regulatory Filings' (RNS) category.
2017-03-30 English
Director's Dealing 2017
Director's Dealing Classification · 99% confidence The document text is structured as a formal notification detailing transactions (specifically 'Tildeling af Restricted Stock Units' and 'Tildeling af warrants') conducted by individuals with managerial responsibilities ('personer med ledelsesansvar') and persons closely associated with them, involving shares of the issuer (Genmab A/S). This format, which reports personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing reports. The Danish terms used, such as 'personer med ledelsesansvar' (persons discharging managerial responsibilities - PDMR) and the tabular format reporting transaction details, are characteristic of MAR (Market Abuse Regulation) filings concerning insider transactions, which map to the 'Director's Dealing' category. Therefore, the appropriate filing type code is DIRS.
2017-03-29 English
Director's Dealing 2017
Director's Dealing Classification · 98% confidence The document is titled "Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them." It details transactions (specifically 'Grant of Restricted Stock Units' and 'Grant of warrants') conducted by individuals holding managerial positions (Executive Vice President & Chief Development Officer, Board member) in the issuer (Genmab A/S). This structure and content directly correspond to regulatory filings reporting insider transactions or director's dealings. Comparing this to the provided definitions, 'Director's Dealing (Code: DIRS)' is the most appropriate classification.
2017-03-29 Danish
Remuneration Information 2017
Remuneration Information Classification · 99% confidence The document is titled 'Selskabsmeddelelse' (Company Announcement) and dated March 29, 2017. The content explicitly details the board's decision to grant restricted stock units (RSUs) and warrants to new board members and a new director. This action directly relates to executive compensation, incentive plans, and the issuance of equity instruments to management/directors. While it touches upon capital structure (SHA/CAP), the primary focus is on the remuneration/incentive awards for key personnel. This aligns most closely with the scope of Remuneration Information (DEF 14A), which covers compensation for top executives and directors, or potentially Director's Dealing (DIRS) if it were a transaction report, but here it is an award grant. Given the context of granting stock units and warrants as part of incentive plans to new management/directors, DEF 14A (Remuneration Information) is the most appropriate fit, as these grants are compensation elements. It is not a general regulatory filing (RNS) because it fits a specific category, nor is it a general capital change (SHA) as it is specifically tied to executive incentive compensation.
2017-03-29 Danish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.